Published in Am J Physiol Gastrointest Liver Physiol on August 19, 2010
Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol (2012) 1.17
Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet. Genes Nutr (2012) 1.09
The metabolic burden of methyl donor deficiency with focus on the betaine homocysteine methyltransferase pathway. Nutrients (2013) 1.04
Additive effects of nicotine and high-fat diet on hepatic steatosis in male mice. Endocrinology (2012) 0.91
Methyl-donor supplementation in obese mice prevents the progression of NAFLD, activates AMPK and decreases acyl-carnitine levels. Mol Metab (2014) 0.89
Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. PLoS One (2015) 0.87
Metabolic crosstalk between choline/1-carbon metabolism and energy homeostasis. Clin Chem Lab Med (2013) 0.87
Effects of betaine on body composition, performance, and homocysteine thiolactone. J Int Soc Sports Nutr (2013) 0.87
Herbal products: benefits, limits, and applications in chronic liver disease. Evid Based Complement Alternat Med (2012) 0.86
Plasma choline metabolites associate with metabolic stress among young overweight men in a genotype-specific manner. Nutr Diabetes (2012) 0.84
Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. Int J Endocrinol (2013) 0.84
Betaine supplementation in maternal diet modulates the epigenetic regulation of hepatic gluconeogenic genes in neonatal piglets. PLoS One (2014) 0.81
Rectification of impaired adipose tissue methylation status and lipolytic response contributes to hepatoprotective effect of betaine in a mouse model of alcoholic liver disease. Br J Pharmacol (2014) 0.81
Additive effects of nicotine and high-fat diet on hepatocellular apoptosis in mice: involvement of caspase 2 and inducible nitric oxide synthase-mediated intrinsic pathway signaling. Horm Metab Res (2014) 0.79
Dietary Betaine Supplementation Increases Fgf21 Levels to Improve Glucose Homeostasis and Reduce Hepatic Lipid Accumulation in Mice. Diabetes (2016) 0.78
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract (2016) 0.77
Betaine and nonalcoholic steatohepatitis: back to the future? World J Gastroenterol (2011) 0.76
Alleviation of Carbon-Tetrachloride-Induced Liver Injury and Fibrosis by Betaine Supplementation in Chickens. Evid Based Complement Alternat Med (2015) 0.76
Betaine Alleviates Hypertriglycemia and Tau Hyperphosphorylation in db/db Mice. Toxicol Res (2013) 0.75
Nopal feeding reduces adiposity, intestinal inflammation and shifts the cecal microbiota and metabolism in high-fat fed rats. PLoS One (2017) 0.75
In ovo injection of betaine alleviates corticosterone-induced fatty liver in chickens through epigenetic modifications. Sci Rep (2017) 0.75
Modified SJH alleviates FFAs-induced hepatic steatosis through leptin signaling pathways. Sci Rep (2017) 0.75
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1996) 26.30
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol (1997) 15.32
Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature (2003) 9.77
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest (2005) 9.09
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem (2005) 5.62
Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology (1994) 5.22
Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology (1990) 3.63
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology (2003) 3.18
Macromolecular crowding: qualitative and semiquantitative successes, quantitative challenges. Biochim Biophys Acta (2003) 3.00
Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol (2005) 2.84
Betaine in human nutrition. Am J Clin Nutr (2004) 2.78
Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr (2003) 2.44
Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr (1991) 2.41
Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab (2003) 2.21
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol (2001) 2.11
Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. Am J Physiol Endocrinol Metab (2002) 1.77
Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A (1994) 1.71
Determination of choline, betaine, and dimethylglycine in plasma by a high-throughput method based on normal-phase chromatography-tandem mass spectrometry. Clin Chem (2003) 1.70
Cell volume regulation: osmolytes, osmolyte transport, and signal transduction. Rev Physiol Biochem Pharmacol (2003) 1.65
Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes (2002) 1.59
The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. Clin Biochem (2010) 1.43
Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. J Hepatol (2006) 1.39
Mechanisms by which liver-specific PEPCK knockout mice preserve euglycemia during starvation. Diabetes (2003) 1.36
Phosphoinositide 3-kinases as a common platform for multi-hormone signaling. J Endocrinol (2007) 1.35
Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology (2002) 1.27
Dietary betaine promotes generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration. Alcohol Clin Exp Res (1993) 1.24
Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J Pharmacol Exp Ther (2005) 1.15
Betaine administration corrects ethanol-induced defective VLDL secretion. Mol Cell Biochem (2009) 1.12
Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am J Physiol Gastrointest Liver Physiol (2007) 1.12
Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology (2007) 1.11
Hyperosmotic stress inhibits insulin receptor substrate-1 function by distinct mechanisms in 3T3-L1 adipocytes. J Biol Chem (2003) 1.10
Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. Eur J Biochem (2003) 1.10
Swelling of hepatocytes injured by oxidative stress suggests pathological changes related to macromolecular crowding. Med Hypotheses (2005) 1.09
Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J Nutr (2008) 1.08
Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol (2008) 1.07
Betaine, ethanol, and the liver: a review. Alcohol (1997) 1.04
Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol (2010) 1.03
Osmotic shock inhibits insulin signaling by maintaining Akt/protein kinase B in an inactive dephosphorylated state. Mol Cell Biol (1999) 1.02
Isocratic high performance liquid chromatographic analysis of S-adenosylmethionine and S-adenosylhomocysteine in animal tissues: the effect of exposure to nitrous oxide. Biomed Chromatogr (1990) 1.00
Insights into the requirement of phosphatidylcholine synthesis for liver function in mice. J Lipid Res (2003) 0.94
Effects of betaine supplementation on hepatic metabolism of sulfur-containing amino acids in mice. J Hepatol (2005) 0.92
Protein arginine methylation regulates insulin signaling in L6 skeletal muscle cells. Biochem Biophys Res Commun (2007) 0.90
Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol (2009) 0.88
Alleviation of dimethylnitrosamine-induced liver injury and fibrosis by betaine supplementation in rats. Chem Biol Interact (2008) 0.84
Impaired glucose tolerance and increased weight gain in transgenic rats overexpressing a non-insulin-responsive phosphoenolpyruvate carboxykinase gene. Mol Endocrinol (1995) 0.83
Impaired PRMT1 activity in the liver and pancreas of type 2 diabetic Goto-Kakizaki rats. Life Sci (2009) 0.82
Involvement of PRMT1 in hnRNPQ activation and internalization of insulin receptor. Biochem Biophys Res Commun (2008) 0.82
Osmotic regulation of insulin-induced mitogen-activated protein kinase phosphatase (MKP-1) expression in H4IIE rat hepatoma cells. Biochem J (2003) 0.80
Osmosensing and osmosignaling in the liver. Wien Med Wochenschr (2008) 0.77
Features of syndrome X develop in transgenic rats expressing a non-insulin responsive phosphoenolpyruvate carboxykinase gene. Diabetologia (1999) 0.77
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA (2008) 7.35
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Alcoholic hepatitis. N Engl J Med (2009) 4.98
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry (2012) 3.73
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med (2008) 3.19
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 3.05
Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol (2002) 3.01
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
NOTCH reprograms mitochondrial metabolism for proinflammatory macrophage activation. J Clin Invest (2015) 2.93
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res (2007) 2.61
PNPASE regulates RNA import into mitochondria. Cell (2010) 2.54
The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest (2007) 2.48
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology (2014) 2.17
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio (2012) 2.15
Emerging role of epigenetics in the actions of alcohol. Alcohol Clin Exp Res (2008) 2.14
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Impaired autophagic flux mediates acinar cell vacuole formation and trypsinogen activation in rodent models of acute pancreatitis. J Clin Invest (2009) 2.06
Adaptive unfolded protein response attenuates alcohol-induced pancreatic damage. Gastroenterology (2010) 2.00
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
GABA, gamma-hydroxybutyric acid, and neurological disease. Ann Neurol (2003) 1.91
Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut (2010) 1.83
Regulation of murine cardiac 20S proteasomes: role of associating partners. Circ Res (2006) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun (2003) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Steatohepatitis induced by intragastric overfeeding in mice. Hepatology (2005) 1.73
Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry (2007) 1.72
Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med (2012) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Heterogeneity in the prevalence of methylenetetrahydrofolate reductase gene polymorphisms in women of different ethnic groups. J Am Diet Assoc (2003) 1.69
Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol (2010) 1.68
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology (2008) 1.66
Epidemiology of alcoholic liver disease. Semin Liver Dis (2004) 1.66
Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry (2004) 1.65
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol (2012) 1.55
The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J Neurochem (2004) 1.55
The ratio of arginine to dimethylarginines is reduced and predicts outcomes in patients with severe sepsis. Crit Care Med (2011) 1.54
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52
Mammalian polynucleotide phosphorylase is an intermembrane space RNase that maintains mitochondrial homeostasis. Mol Cell Biol (2006) 1.49
Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis. Exp Mol Pathol (2008) 1.48
Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr (2002) 1.47
High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A (2006) 1.47
Creatine metabolism in combined methylmalonic aciduria and homocystinuria. Ann Neurol (2005) 1.46
Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol (2005) 1.45
Effect of hyperhomocysteinemia on protein C activation and activity. Blood (2002) 1.45
A new function in translocation for the mitochondrial i-AAA protease Yme1: import of polynucleotide phosphorylase into the intermembrane space. Mol Cell Biol (2006) 1.44
Histologic evaluation and treatment outcome after sequential radiofrequency ablation and hepatic resection for primary and metastatic tumors. Am Surg (2002) 1.43
Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem (2003) 1.42
Epigenetic mechanisms regulate Mallory Denk body formation in the livers of drug-primed mice. Exp Mol Pathol (2008) 1.41
Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J Hepatol (2011) 1.39
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest (2013) 1.37
Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res (2004) 1.37
Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke (2004) 1.37
Gene expression patterns of the liver in response to alcohol: in vivo and in vitro models compared. Exp Mol Pathol (2006) 1.36
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatology (2009) 1.32
CYP2E1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp Mol Pathol (2006) 1.31
SAMe prevents the up regulation of toll-like receptor signaling in Mallory-Denk body forming hepatocytes. Exp Mol Pathol (2010) 1.29
Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology (2002) 1.27
Betaine prevents Mallory-Denk body formation in drug-primed mice by epigenetic mechanisms. Exp Mol Pathol (2008) 1.27
Chronic ethanol feeding alters hepatocyte memory which is not altered by acute feeding. Alcohol Clin Exp Res (2009) 1.27
The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol (2010) 1.27
Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci U S A (2002) 1.26
The importance of cycling of blood alcohol levels in the pathogenesis of experimental alcoholic liver disease in rats. Gastroenterology (2002) 1.24
Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Mol Genet Metab (2007) 1.24
A phagocytic cell line markedly improves survival of infected neutropenic mice. J Leukoc Biol (2005) 1.23
Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci (2007) 1.22
The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. Hepatology (2009) 1.21
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood (2006) 1.20
Structure of cerebral arterioles in cystathionine beta-synthase-deficient mice. Circ Res (2002) 1.20
Mallory body (cytokeratin aggresomes) formation is prevented in vitro by p38 inhibitor. Exp Mol Pathol (2006) 1.20
Impaired liver regeneration in mice lacking methionine adenosyltransferase 1A. FASEB J (2004) 1.19
Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice. Hepatology (2010) 1.19
Islet cell tumor arising from a heterotopic pancreas in the duodenal wall with ulceration. Exp Mol Pathol (2004) 1.19
Hypermethylation of Fads2 and altered hepatic fatty acid and phospholipid metabolism in mice with hyperhomocysteinemia. J Biol Chem (2007) 1.18
The role of cytokines in UbD promoter regulation and Mallory-Denk body-like aggresomes. Exp Mol Pathol (2010) 1.18
Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol (2006) 1.18